Vemurafenib Pathway, Pharmacodynamics

No Pathway Network information available for Vemurafenib Pathway, Pharmacodynamics

Pathways in the Vemurafenib Pathway, Pharmacodynamics SuperPath

#	Name	Source	Genes
1	Vemurafenib Pathway, Pharmacodynamics	PharmGKB	ARAF BRAF EGF EGFR ETS1 FGF1 FGF2 FGF3 FGF4 FGF5 FGF6 FGF7 FGFR1 FGFR2 FGFR3 FGFR3P1 FGFR4 FLT1 FLT4 GRB2 HRAS JUN KDR KRAS MAP2K1 MAP2K2 MAPK1 MAPK3 MRAS MYC NRAS PDGFA PDGFB PDGFC PDGFD PDGFRA PDGFRB RAF1 RRAS SOS1 SOS2 VEGFA VEGFB (see all 43) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	RRAS	RAS Related	Protein Coding	1
2	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
3	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	1
4	VEGFB	Vascular Endothelial Growth Factor B	Protein Coding	1
5	FGF1	Fibroblast Growth Factor 1	Protein Coding	1
6	FGF2	Fibroblast Growth Factor 2	Protein Coding	1
7	FGF3	Fibroblast Growth Factor 3	Protein Coding	1
8	FGF4	Fibroblast Growth Factor 4	Protein Coding	1
9	FGF5	Fibroblast Growth Factor 5	Protein Coding	1
10	FGF6	Fibroblast Growth Factor 6	Protein Coding	1
11	FGF7	Fibroblast Growth Factor 7	Protein Coding	1
12	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	1
13	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1
14	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	1
15	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	1
16	GRB2	Growth Factor Receptor Bound Protein 2	Protein Coding	1
17	SOS1	SOS Ras/Rac Guanine Nucleotide Exchange Factor 1	Protein Coding	1
18	SOS2	SOS Ras/Rho Guanine Nucleotide Exchange Factor 2	Protein Coding	1
19	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
20	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	1
21	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
22	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	1
23	KDR	Kinase Insert Domain Receptor	Protein Coding	1
24	PDGFA	Platelet Derived Growth Factor Subunit A	Protein Coding	1
25	PDGFB	Platelet Derived Growth Factor Subunit B	Protein Coding	1
26	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	1
27	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	1
28	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	1
29	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	1
30	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	1
31	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	1
32	ETS1	ETS Proto-Oncogene 1, Transcription Factor	Protein Coding	1
33	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1
34	MRAS	Muscle RAS Oncogene Homolog	Protein Coding	1
35	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	1
36	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	1
37	PDGFC	Platelet Derived Growth Factor C	Protein Coding	1
38	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	1
39	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	1
40	EGF	Epidermal Growth Factor	Protein Coding	1
41	EGFR	Epidermal Growth Factor Receptor	Protein Coding	1
42	PDGFD	Platelet Derived Growth Factor D	Protein Coding	1
43	FGFR3P1	Fibroblast Growth Factor Receptor 3 Pseudogene 1	Pseudogene	1

Disorders associated with Vemurafenib Pathway, Pharmacodynamics SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Rasopathy	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, MRAS, NRAS, RAF1, SOS1, SOS2	11.52
2	Noonan syndrome 1	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, MRAS, NRAS, RAF1, RRAS, SOS1, SOS2	10.94
3	Lung non-small cell carcinoma	Enrichment	BRAF, EGFR, HRAS, KRAS, MAP2K1, NRAS	10.88
4	Noonan syndrome and noonan-related syndrome	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SOS1	10.50
5	Cardiofaciocutaneous syndrome 1	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	9.95
6	Cardiofaciocutaneous syndrome	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	9.95
7	Nevus, epidermal	Enrichment	FGFR3, HRAS, KRAS, NRAS	8.51
8	Noonan syndrome 3	Enrichment	HRAS, KRAS, RAF1, SOS1	8.51
9	Pilomyxoid astrocytoma	Enrichment	BRAF, FGFR1, KRAS, RAF1	8.51
10	Melanocytic nevus syndrome, congenital	Enrichment	BRAF, HRAS, NRAS, RAF1	8.21
11	Langerhans cell histiocytosis	Enrichment	BRAF, MAP2K1, NRAS	7.53
12	Schimmelpenning-feuerstein-mims syndrome	Enrichment	HRAS, KRAS, NRAS	6.93
13	Primary hypereosinophilic syndrome	Enrichment	FGFR1, PDGFRA, PDGFRB	6.53
14	Lung squamous cell carcinoma	Enrichment	EGFR, FGFR3, KRAS	6.23
15	Thyroid cancer, nonmedullary, 2	Enrichment	BRAF, HRAS, NRAS	5.99
16	Follicular thyroid carcinoma	Enrichment	BRAF, HRAS, NRAS	5.99
17	Bladder cancer	Enrichment	EGFR, FGFR3, HRAS, KRAS	5.71
18	Differentiated thyroid carcinoma	Enrichment	BRAF, HRAS, KRAS, NRAS	5.71
19	Juvenile myelomonocytic leukemia	Enrichment	KRAS, NRAS, RRAS	5.19
20	Lip and oral cavity carcinoma	Enrichment	BRAF, EGFR, HRAS	5.19
21	Pulmonic stenosis	Enrichment	BRAF, SOS1	5.01
22	Pfeiffer syndrome	Enrichment	FGFR1, FGFR2	5.01
23	Jackson-weiss syndrome	Enrichment	FGFR1, FGFR2	5.01
24	Encephalocraniocutaneous lipomatosis	Enrichment	FGFR1, KRAS	5.01
25	Ras-associated autoimmune leukoproliferative disorder	Enrichment	KRAS, NRAS	5.01
26	Lung cancer susceptibility 3	Enrichment	BRAF, EGFR, KRAS	4.98
27	Gliosarcoma	Enrichment	EGFR, FGFR1, FGFR3	4.79
28	Giant cell glioblastoma	Enrichment	EGFR, FGFR1, FGFR3	4.71
29	Arteriovenous malformations of the brain	Enrichment	BRAF, EGFR, KRAS	4.56
30	Crouzon syndrome	Enrichment	FGFR2, FGFR3	4.53
31	Lacrimoauriculodentodigital syndrome 1	Enrichment	FGFR2, FGFR3	4.53
32	Large congenital melanocytic nevus	Enrichment	HRAS, NRAS	4.53
33	Spermatocytoma	Enrichment	FGFR3, HRAS	4.53
34	Saethre-chotzen syndrome	Enrichment	FGFR2, FGFR3	4.23
35	Chronic myelogenous leukemia, bcr-abl1 positive	Enrichment	KRAS, NRAS	4.23
36	Noonan syndrome with multiple lentigines	Enrichment	BRAF, RAF1	4.23
37	Hemifacial hyperplasia	Enrichment	FGFR2, FGFR3	4.01
38	Non-immune hydrops fetalis	Enrichment	FLT4, HRAS, KRAS	3.90
39	Lung cancer	Enrichment	BRAF, EGFR, KRAS	3.86
40	Hemangioma, capillary infantile	Enrichment	FLT4, KDR	3.84
41	Colorectal cancer	Enrichment	BRAF, FGFR2, FGFR3, NRAS	3.79
42	Capillary malformation-arteriovenous malformation 1	Enrichment	KRAS, MAP2K1	3.69
43	Leukemia, chronic myeloid	Enrichment	KRAS, NRAS	3.69
44	Gallbladder cancer	Enrichment	BRAF, KRAS	3.69
45	Basal ganglia calcification, idiopathic, 1	Enrichment	PDGFB, PDGFRB	3.57
46	Arteriovenous malformation	Enrichment	HRAS, MAP2K1	3.46
47	Myopathy, x-linked, with excessive autophagy	Enrichment	HRAS, MAP2K1	3.36
48	Myeloma, multiple	Enrichment	BRAF, FGFR3, KRAS	3.14
49	Hydrocephalus	Enrichment	FGFR2, PDGFRB	3.00
50	Dandy-walker syndrome	Enrichment	BRAF, PDGFRB	2.89
51	Craniosynostosis	Enrichment	FGFR2, FGFR3	2.75
52	Tetralogy of fallot	Enrichment	FLT4, KDR	2.52
53	Hydrops fetalis, nonimmune	Enrichment	FLT4, HRAS	2.52
54	Hypochondroplasia	Enrichment	FGFR3	2.50
55	Beare-stevenson cutis gyrata syndrome	Enrichment	FGFR2	2.50
56	Osteoglophonic dysplasia	Enrichment	FGFR1	2.50
57	Thanatophoric dysplasia, type i	Enrichment	FGFR3	2.50
58	Trigonocephaly 1	Enrichment	FGFR1	2.50
59	Oculoectodermal syndrome	Enrichment	KRAS	2.50
60	Muenke syndrome	Enrichment	FGFR3	2.50
61	Pallister-killian syndrome	Enrichment	ARAF	2.50
62	Premature aging syndrome, penttinen type	Enrichment	PDGFRB	2.50
63	Noonan syndrome 5	Enrichment	RAF1	2.50
64	Hypomagnesemia 4, renal	Enrichment	EGF	2.50
65	Noonan syndrome 4	Enrichment	SOS1	2.50
66	Hypereosinophilic syndrome, idiopathic	Enrichment	PDGFRA	2.50
67	Scaphocephaly, maxillary retrusion, and impaired intellectual development	Enrichment	FGFR2	2.50
68	Melorheostosis, isolated	Enrichment	MAP2K1	2.50
69	Noonan syndrome 7	Enrichment	BRAF	2.50
70	Leopard syndrome 3	Enrichment	BRAF	2.50
71	Apert syndrome	Enrichment	FGFR2	2.50
72	Basal ganglia calcification, idiopathic, 5	Enrichment	PDGFB	2.50
73	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	2.50
74	Cardiofaciocutaneous syndrome 3	Enrichment	MAP2K1	2.50
75	Myofibromatosis, infantile, 1	Enrichment	PDGFRB	2.50
76	Melanosis, neurocutaneous	Enrichment	NRAS	2.50
77	Thanatophoric dysplasia, type ii	Enrichment	FGFR3	2.50
78	Noonan syndrome 9	Enrichment	SOS2	2.50
79	Noonan syndrome 6	Enrichment	NRAS	2.50
80	Gist-plus syndrome	Enrichment	PDGFRA	2.50
81	Camptodactyly, tall stature, and hearing loss syndrome	Enrichment	FGFR3	2.50
82	Bent bone dysplasia syndrome 1	Enrichment	FGFR2	2.50
83	Noonan syndrome 11	Enrichment	MRAS	2.50
84	Noonan syndrome 13	Enrichment	MAPK1	2.50
85	Myeloid and lymphoid neoplasms associated with pdgfra rearrangement	Enrichment	PDGFRA	2.50
86	Familial isolated trichomegaly	Enrichment	FGF5	2.50
87	Cardiofaciocutaneous syndrome 2	Enrichment	KRAS	2.50
88	Microvascular complications of diabetes 1	Enrichment	VEGFA	2.50
89	Lymphangioma	Enrichment	BRAF	2.50
90	Crouzon syndrome with acanthosis nigricans	Enrichment	FGFR3	2.50
91	Phace association	Enrichment	BRAF	2.50
92	Melorheostosis	Enrichment	MAP2K1	2.50
93	Leopard syndrome 2	Enrichment	RAF1	2.50
94	Basal ganglia calcification, idiopathic, 4	Enrichment	PDGFRB	2.50
95	Cardiofaciocutaneous syndrome 4	Enrichment	MAP2K2	2.50
96	Myeloid and lymphoid neoplasms associated with pdgfrb rearrangement	Enrichment	PDGFRB	2.50
97	Achondroplasia, severe, with developmental delay and acanthosis nigricans	Enrichment	FGFR3	2.50
98	Kosaki overgrowth syndrome	Enrichment	PDGFRB	2.50
99	Hartsfield syndrome	Enrichment	FGFR1	2.50
100	Congenital heart defects, multiple types, 7	Enrichment	FLT4	2.50
101	Ocular pterygium-digital keloid dysplasia syndrome	Enrichment	PDGFRB	2.50
102	Trigonitis	Enrichment	RAF1	2.50
103	Tufted angioma of skin	Enrichment	KDR	2.50
104	Lacrimoauriculodentodigital syndrome 2	Enrichment	FGFR3	2.50
105	Short-rib thoracic dysplasia 22 without polydactyly	Enrichment	FGF4	2.50
106	Congenital pulmonary airway malformation	Enrichment	KRAS	2.50
107	Fgfr3-related chondrodysplasia	Enrichment	FGFR3	2.50
108	Syringocystadenoma papilliferum	Enrichment	BRAF	2.50
109	Camptodactyly-tall stature-scoliosis-hearing loss syndrome	Enrichment	FGFR3	2.50
110	Ganglioglioma	Enrichment	BRAF	2.50
111	Nongerminomatous germ cell tumor	Enrichment	BRAF	2.50
112	Phace syndrome	Enrichment	BRAF	2.50
113	Phakomatosis pigmentokeratotica	Enrichment	HRAS	2.50
114	Classic hairy cell leukemia	Enrichment	BRAF	2.50
115	Hartsfield-bixler-demyer syndrome	Enrichment	FGFR1	2.50
116	Egf-related primary hypomagnesemia with intellectual disability	Enrichment	EGF	2.50
117	Non-syndromic unicoronal craniosynostosis	Enrichment	FGFR2	2.50
118	Neurocutaneous melanocytosis	Enrichment	NRAS	2.50
119	Ovarian cancer	Enrichment	EGFR, KRAS, PDGFRA	2.40
120	Lymphatic malformation 1	Enrichment	FLT4	2.20
121	Burkitt lymphoma	Enrichment	MYC	2.20
122	Myeloproliferative disorder, chronic, with eosinophilia	Enrichment	PDGFRB	2.20
123	Fibromatosis, gingival, 1	Enrichment	SOS1	2.20
124	Otodental dysplasia	Enrichment	FGF3	2.20
125	Costello syndrome	Enrichment	HRAS	2.20
126	Trichomegaly	Enrichment	FGF5	2.20
127	Intracranial hypertension, idiopathic	Enrichment	FLT4	2.20
128	Dermatofibrosarcoma protuberans	Enrichment	PDGFB	2.20
129	Cervical cancer	Enrichment	FGFR3	2.20
130	Aural atresia, congenital	Enrichment	FGFR2	2.20
131	Keratosis, seborrheic	Enrichment	FGFR3	2.20
132	Deafness, congenital, with inner ear agenesis, microtia, and microdontia	Enrichment	FGF3	2.20
133	Angioma, tufted	Enrichment	KDR	2.20
134	Antley-bixler syndrome without genital anomalies or disordered steroidogenesis	Enrichment	FGFR2	2.20
135	Infantile myofibromatosis	Enrichment	PDGFRB	2.20
136	Split hand-foot malformation	Enrichment	FGFR2	2.20
137	Rosette-forming glioneuronal tumor	Enrichment	FGFR1	2.20
138	Cervix carcinoma	Enrichment	FGFR3	2.20
139	Hereditary lymphedema i	Enrichment	FLT4	2.20
140	Interfrontal craniofaciosynostosis	Enrichment	FGFR1	2.20
141	Autosomal dominant nonsyndromic deafness	Enrichment	FGFR2	2.20
142	Chronic eosinophilic leukemia	Enrichment	PDGFRA	2.20
143	B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality	Enrichment	PDGFRA	2.20
144	Tafro syndrome	Enrichment	MAP2K2	2.20
145	Oculootodental syndrome	Enrichment	FGF3	2.20
146	Wooly hair nevus	Enrichment	HRAS	2.20
147	Leukemia, acute myeloid	Enrichment	KRAS, NRAS	2.15
148	Gastric cancer	Enrichment	FGFR2, KRAS	2.09
149	Achondroplasia	Enrichment	FGFR3	2.02
150	Jacobsen syndrome	Enrichment	ETS1	2.02
151	Hypogonadotropic hypogonadism 2 with or without anosmia	Enrichment	FGFR1	2.02
152	Larsen syndrome	Enrichment	FGFR3	2.02
153	Ataxia-telangiectasia	Enrichment	BRAF	2.02
154	Nuchal bleb, familial	Enrichment	SOS1	2.02
155	Chromosome 8p11 myeloproliferative syndrome	Enrichment	FGFR1	2.02
156	Neonatal nephrocutaneous inflammatory syndrome	Enrichment	EGFR	2.02
157	Tethered spinal cord syndrome	Enrichment	BRAF	2.02
158	High-grade b-cell lymphoma double-hit/triple-hit	Enrichment	MYC	2.02
159	Hamartoma	Enrichment	FGFR3	2.02
160	Testicular germ cell cancer	Enrichment	FGFR3	2.02
161	Neonatal inflammatory skin and bowel disease	Enrichment	EGFR	2.02
162	Testicular cancer	Enrichment	FGFR3	2.02
163	Diffuse gastric and lobular breast cancer syndrome	Enrichment	KRAS	1.90
164	Thyroid cancer, nonmedullary, 1	Enrichment	BRAF	1.90
165	Neurofibromatosis-noonan syndrome	Enrichment	MAP2K2	1.90
166	Chromosome 22q11.2 deletion syndrome, distal	Enrichment	MAPK1	1.90
167	Lung sarcomatoid carcinoma	Enrichment	KRAS	1.90
168	Craniopharyngioma	Enrichment	BRAF	1.90
169	Pilocytic astrocytoma	Enrichment	KRAS	1.90
170	Newborn respiratory distress syndrome	Enrichment	BRAF	1.90
171	Epidermolytic nevus	Enrichment	HRAS	1.90
172	Non-syndromic bicoronal craniosynostosis	Enrichment	FGFR3	1.90
173	Glioma	Enrichment	FGFR2	1.90
174	Gingival fibromatosis	Enrichment	SOS1	1.90
175	Male infertility due to gonadal dysgenesis or sperm disorder	Enrichment	SOS2	1.90
176	Pre-eclampsia	Enrichment	FLT1	1.80
177	Holoprosencephaly	Enrichment	FGFR1	1.80
178	Cowden syndrome 1	Enrichment	EGFR	1.72
179	Split-hand/foot malformation 1	Enrichment	FGFR2	1.72
180	Holoprosencephaly 1	Enrichment	FGFR1	1.72
181	Testicular germ cell tumor	Enrichment	FGFR3	1.72
182	Wilms tumor 5	Enrichment	BRAF	1.72
183	Breast adenocarcinoma	Enrichment	KRAS	1.72
184	46,xy disorder of sex development	Enrichment	FGFR3	1.72
185	Squamous cell carcinoma, head and neck	Enrichment	EGFR	1.66
186	Gastrointestinal stromal tumor	Enrichment	PDGFRA	1.66
187	Breast cancer	Enrichment	JUN, KRAS	1.63
188	Lymphoma, non-hodgkin, familial	Enrichment	BRAF	1.60
189	Dilated cardiomyopathy	Enrichment	BRAF, RAF1	1.58
190	Cardiomyopathy, familial hypertrophic, 4	Enrichment	BRAF	1.55
191	Adult hepatocellular carcinoma	Enrichment	EGF	1.55
192	Hypogonadotropic hypogonadism	Enrichment	FGFR1	1.55
193	Primary hyperaldosteronism	Enrichment	BRAF	1.55
194	Ventricular septal defect	Enrichment	BRAF	1.55
195	Meier-gorlin syndrome 1	Enrichment	FGFR2	1.50
196	Melanoma	Enrichment	BRAF	1.50
197	Primary bone dysplasia	Enrichment	FGFR3	1.50
198	Meningioma, familial	Enrichment	PDGFB	1.46
199	Osteochondrodysplasia	Enrichment	FGFR3	1.46
200	Specific learning disability	Enrichment	MAPK1	1.46
201	Septooptic dysplasia	Enrichment	FGFR1	1.43
202	Renal hypodysplasia/aplasia 3	Enrichment	FGFR3	1.43
203	Meningioma	Enrichment	PDGFB	1.43
204	Aortic valve disease 1	Enrichment	SOS1	1.39
205	Protein-deficiency anemia	Enrichment	NRAS	1.39
206	Hypogonadotropic hypogonadism 7 with or without anosmia	Enrichment	FGFR1	1.36
207	Cleft lip/palate	Enrichment	PDGFRA	1.36
208	46,xy partial gonadal dysgenesis	Enrichment	SOS1	1.36
209	Wilms tumor 1	Enrichment	BRAF	1.33
210	Lynch syndrome	Enrichment	KRAS	1.33
211	Rhabdomyosarcoma	Enrichment	HRAS	1.30
212	Microform holoprosencephaly	Enrichment	FGFR1	1.30
213	Lobar holoprosencephaly	Enrichment	FGFR1	1.30
214	Melanoma, cutaneous malignant 1	Enrichment	BRAF	1.28
215	Heart, malformation of	Enrichment	MAPK1	1.26
216	Semilobar holoprosencephaly	Enrichment	FGFR1	1.26
217	Normosmic congenital hypogonadotropic hypogonadism	Enrichment	FGFR1	1.26
218	Diffuse large b-cell lymphoma	Enrichment	BRAF	1.23
219	Endometrial cancer	Enrichment	FGFR2	1.19
220	Hepatoblastoma	Enrichment	FGFR3	1.19
221	Inherited cancer-predisposing syndrome	Enrichment	EGFR, PDGFRA	1.18
222	Tooth agenesis	Enrichment	FGFR1	1.17
223	Kallmann syndrome	Enrichment	FGFR1	1.15
224	Precursor t-cell acute lymphoblastic leukemia	Enrichment	MYC	1.15
225	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	1.13
226	Pancreatic cancer	Enrichment	KRAS	1.12
227	Connective tissue disease	Enrichment	FGFR3	1.01
228	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	1.00
229	Left ventricular noncompaction	Enrichment	RAF1	0.98
230	Systemic lupus erythematosus	Enrichment	ETS1	0.93
231	Cerebral palsy	Enrichment	PDGFRB	0.93
232	Hereditary breast carcinoma	Enrichment	KRAS	0.88
233	Hypertelorism	Enrichment	FGFR2	0.82
234	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	0.81
235	Hereditary breast ovarian cancer syndrome	Enrichment	KRAS	0.79
236	Primary ovarian insufficiency	Enrichment	KDR	0.77
237	Congenital nervous system abnormality	Enrichment	FGFR3	0.54
238	Nervous system disease	Enrichment	FGFR3	0.54
239	Autism spectrum disorder	Enrichment	MAP2K1	0.53
240	Microcephaly	Enrichment	MAPK1	0.49

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Vemurafenib Pathway, Pharmacodynamics

Pathway Network for Vemurafenib Pathway, Pharmacodynamics

Member Pathways for Vemurafenib Pathway, Pharmacodynamics

Pathways in the Vemurafenib Pathway, Pharmacodynamics SuperPath

Associated Genes for Vemurafenib Pathway, Pharmacodynamics

Associated Disorders for Vemurafenib Pathway, Pharmacodynamics

Disorders associated with Vemurafenib Pathway, Pharmacodynamics SuperPath

STRING Interaction Network for Vemurafenib Pathway, Pharmacodynamics

Sources for Vemurafenib Pathway, Pharmacodynamics